Oral SERDs Explained: A New Option for Breast Cancer Patients
Oral selective estrogen receptor degraders (SERDs) are reshaping hormone receptor-positive (HR+) metastatic breast cancer treatment. Could they replace fulvestrant? Dr. Francisco J. Esteva explains the science, key clinical trials, and what these advances mean for patients and oncologists. #cancer #cancertreatment #breastcancer Chapters: 0:00 Introduction 01:58 Fulvestrant: first SERD 02:22 Elacestrant: first oral SERD approved 02:36. Liquid biopsy to detect mutant ESR1 03:35 SERENA-6 trial: camizestrant in first line MBC 05:05 Conclusions About Dr. Esteva Francisco J. Esteva, MD, PhD is a medical oncologist based in New York with a specialization in breast cancer. He completed an Oncology Fellowship at Georgetown University Hospital and an Internal Medicine Residency at Cooper Medical School of Rowan University. Dr. Esteva serves as Division Chief at Lenox Hill Hospital and has previously held faculty appointments at NYU and The University of Texas MD Anderson Cancer Center. He has authored numerous peer-reviewed publications and has led more than 100 clinical trials focused on breast cancer treatment, diagnostics, and predictive biomarkers. His honors include Fellowship in the American College of Physicians, election to the American Society for Clinical Investigation, the 2019 Physician of Impact Award from Susan G. Komen NYC, and election to the NYC American Cancer Society Board of Advisors in 2024. Medical Disclaimer The content in this video is intended for informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek guidance from your physician or another qualified health professional regarding any medical condition. Do not disregard professional medical advice or delay seeking care because of information presented in this video. The views shared in this video represent Dr. Esteva’s personal opinions and do not reflect those of his employer. Non-Sponsorship & Affiliation Disclaimer This video is not sponsored. Any mention of products, medications, or brands is for educational purposes only and does not imply endorsement. Advertisements that may appear are placed by YouTube; I am not affiliated with, nor do I endorse, any advertised products or services.

Advanced HR-Positive Breast Cancer: Oral SERDs in Focus

This Isn't Experimental: Breast Cancer Just Got 3 NEW DRUGS | Cancer Drug Designer

Breaking Down Aromatase Inhibitors: What Doctors Don't Say

What Is DCIS? The Breast Cancer Diagnosis That's Not Quite Cancer

2025 SABCS Highlights: Advances in Oral SERDs for Breast Cancer | Dana-Farber Cancer Institute

Clear Margins… But Risk Remains

Breast Cancer: MUST know details (ER, PR, HER2, Ki67, etc)

Understanding Enhertu for HER2-Low & HER2+ Metastatic Breast Cancer

Why Is Treatment SO LONG? Tamoxifen & Aromatase Inhibitors for HR+ Breast Cancer

Breast Cancer Recurrence: Am I Cured?

25 Brutal Truths a Breast Surgeon Learned about Breast Cancer

EMERALD lead to the Elacestrant FDA Approval - OncBrothers in discussion w/ Dr. Virginia Kaklamani

Ask the Expert: Stephanie Graff answers your breast cancer questions at ESMO 2025

Breast Cancer ESMO 2025 Highlights: MonarchE, NATALEE, VIKTORIA1, evERA, DESTINY, ASCENT, TROPION

HER2 Negative? Why It's No Longer So Simple

CDK 4/6 Inhibitors for Breast Cancer: How They Work, Who Gets Them, What to Expect

Use These 5 Food Hacks To Heal The Body & STARVE CANCER I Dr. William Li

What Are SERDs for HR+ Breast Cancer? How They Work and Who Benefits

Experiences With Oral SERDs for HR+/HER2- Metastatic Breast Cancer

